J. Infante

3.1k total citations
17 papers, 273 citations indexed

About

J. Infante is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, J. Infante has authored 17 papers receiving a total of 273 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 8 papers in Oncology and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in J. Infante's work include Colorectal Cancer Treatments and Studies (5 papers), Radiopharmaceutical Chemistry and Applications (2 papers) and Cancer Research and Treatments (2 papers). J. Infante is often cited by papers focused on Colorectal Cancer Treatments and Studies (5 papers), Radiopharmaceutical Chemistry and Applications (2 papers) and Cancer Research and Treatments (2 papers). J. Infante collaborates with scholars based in United States, United Kingdom and Australia. J. Infante's co-authors include Howard A. Burris, Suzanne F. Jones, Susan Lee, Amita Patnaik, Kyriakos P. Papadopoulos, Jamal Tarazi, Peter P. Lee, Peter J. Rosen, Richard E. Cutler and Edward A. Sausville and has published in prestigious journals such as Cancer Research, British Journal of Cancer and Annals of Oncology.

In The Last Decade

J. Infante

17 papers receiving 271 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
J. Infante United States 8 156 137 66 49 38 17 273
Anna Elisabetta Brunetti Italy 10 138 0.9× 175 1.3× 45 0.7× 34 0.7× 60 1.6× 18 336
Melanie Dujka United States 7 223 1.4× 122 0.9× 44 0.7× 48 1.0× 56 1.5× 12 344
Amanda L. Robichaud United States 7 280 1.8× 105 0.8× 52 0.8× 36 0.7× 47 1.2× 9 370
Kallappa M. Koti United States 5 162 1.0× 136 1.0× 41 0.6× 91 1.9× 26 0.7× 14 292
Mara Mazzoni Italy 10 196 1.3× 117 0.9× 59 0.9× 55 1.1× 58 1.5× 14 330
Tao Osgood United States 6 158 1.0× 185 1.4× 58 0.9× 22 0.4× 43 1.1× 14 308
Yuanjue Sun China 7 295 1.9× 128 0.9× 66 1.0× 31 0.6× 54 1.4× 8 381
Zhihua Li China 6 212 1.4× 97 0.7× 34 0.5× 52 1.1× 80 2.1× 15 334
Xiaojie Xu China 11 173 1.1× 123 0.9× 46 0.7× 34 0.7× 72 1.9× 19 354

Countries citing papers authored by J. Infante

Since Specialization
Citations

This map shows the geographic impact of J. Infante's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Infante with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Infante more than expected).

Fields of papers citing papers by J. Infante

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Infante. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Infante. The network helps show where J. Infante may publish in the future.

Co-authorship network of co-authors of J. Infante

This figure shows the co-authorship network connecting the top 25 collaborators of J. Infante. A scholar is included among the top collaborators of J. Infante based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Infante. J. Infante is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Karp, Daniel D., D. Ross Camidge, J. Infante, et al.. (2022). Phase I study of PT-112, a novel pyrophosphate-platinum immunogenic cell death inducer, in advanced solid tumours. EClinicalMedicine. 49. 101430–101430. 25 indexed citations
2.
Chowdhury, Simon, J. Infante, Robert D. Hawkins, et al.. (2021). A Phase I/II Study to Assess the Safety and Efficacy of Pazopanib and Pembrolizumab Combination Therapy in Patients with Advanced Renal Cell Carcinoma. Clinical Genitourinary Cancer. 19(5). 434–446. 19 indexed citations
3.
Kaplan, Jason, Leo I. Gordon, J. Infante, et al.. (2017). TAK‐659, AN INVESTIGATIONAL REVERSIBLE DUAL SYK/FLT‐3 INHIBITOR, IN PATIENTS WITH LYMPHOMA: UPDATED RESULTS FROM DOSE‐ESCALATION AND EXPANSION COHORTS OF a PHASE 1 STUDY. Hematological Oncology. 35(S2). 72–74. 5 indexed citations
4.
Meric‐Bernstam, Funda, Nizar M. Tannir, James J. Harding, et al.. (2016). Phase 1 study of CB-839, a small molecule inhibitor of glutaminase, in combination with everolimus in patients (pts) with clear cell and papillary renal cell cancer (RCC). European Journal of Cancer. 69. S12–S13. 9 indexed citations
5.
6.
Meric‐Bernstam, Funda, Angela DeMichele, Melinda L. Telli, et al.. (2015). Abstract C49: Phase 1 study of CB-839, a first-in-class, orally administered small molecule inhibitor of glutaminase in patients with refractory solid tumors. Molecular Cancer Therapeutics. 14(12_Supplement_2). C49–C49. 4 indexed citations
7.
Gordon, M.S., Monica Mita, Brian I. Rini, et al.. (2015). 354 Phase I study of investigational oral mTORC1/2 inhibitor MLN0128: Expansion phase in patients with renal, endometrial, or bladder cancer. European Journal of Cancer. 51. S72–S72. 3 indexed citations
8.
Hoh, Carl K., Howard A. Burris, Johanna C. Bendell, et al.. (2014). Intermittent dosing of axitinib combined with chemotherapy is supported by 18FLT-PET in gastrointestinal tumours. British Journal of Cancer. 110(4). 875–881. 4 indexed citations
9.
Wong, Harvey, Stephen E. Gould, Nageshwar Budha, et al.. (2013). Learning and Confirming with Preclinical Studies: Modeling and Simulation in the Discovery of GDC-0917, an Inhibitor of Apoptosis Proteins Antagonist. Drug Metabolism and Disposition. 41(12). 2104–2113. 42 indexed citations
10.
Papadopoulos, Kyriakos P., Howard A. Burris, Michael S. Gordon, et al.. (2013). A phase I/II study of carfilzomib 2–10-min infusion in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 72(4). 861–868. 70 indexed citations
11.
Weber, Jeffrey S., Adil Daud, J. Infante, et al.. (2012). 23 Clinical Status of RAF/MEK Inhibitors. European Journal of Cancer. 48. 10–10. 1 indexed citations
12.
Kurkjian, Carla, Peter J.L. Lipman, Chirag Patel, et al.. (2012). 605 A Phase 1, Open-label, Dose-escalation Study of Oral Administration of the Investigational Agent MLN0128 in Combination with Paclitaxel (P) in Patients (pts) with Advanced Solid Malignancies. European Journal of Cancer. 48. 186–186. 3 indexed citations
13.
Kim, Kevin, J. Infante, Roger B. Cohen, et al.. (2011). Abstract B225: A phase I dose-escalation study of selumetinib in combination with docetaxel in patients with advanced solid tumors.. Molecular Cancer Therapeutics. 10(11_Supplement). B225–B225. 11 indexed citations
14.
Infante, J., Geoffrey R. Weiss, Suzanne F. Jones, et al.. (2010). 375 A Phase 1 dose escalation study of the oral heat shock protein 90 (Hsp90) inhibitor PF-04929113/SNX-5422 (PF-113) and its associated ocular toxicity. European Journal of Cancer Supplements. 8(7). 119–119. 4 indexed citations
15.
16.
Infante, J., Elizabeth Claire Dees, Roger B. Cohen, et al.. (2008). 280 POSTER Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of MLN8237, a selective Aurora A kinase inhibitor, in the United States. European Journal of Cancer Supplements. 6(12). 90–91. 13 indexed citations
17.
Torres, M.D. Martínez del Valle, et al.. (1998). [Radionuclide bone scanning in patients with breast carcinoma. Study of lesions by stages, locations and diagnostic assessment].. PubMed. 17(6). 435–41. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Anna Elisabetta Brunetti Breakdown of academic impact, for papers by Melanie Dujka Breakdown of academic impact, for papers by Amanda L. Robichaud Breakdown of academic impact, for papers by Kallappa M. Koti Breakdown of academic impact, for papers by Mara Mazzoni Breakdown of academic impact, for papers by Tao Osgood Breakdown of academic impact, for papers by Yuanjue Sun Breakdown of academic impact, for papers by Zhihua Li Breakdown of academic impact, for papers by Xiaojie Xu
Rankless by CCL
2026